E
CASI icon

Ergoteles’s CASI Pharmaceuticals CASI Stock Holding History

Ergoteles’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,615
Closed -$341K – 1263
2021
Q3 		$341K Sell
28,615
-1,425
-5% -$19.3K 0.01% 743
2021
Q2 		$466K Buy
+30,040
New +$505K 0.01% 847

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ergoteles's CASI Position: Q4 2021 in Review

Ergoteles sold out of CASI Pharmaceuticals (CASI) in Q4 2021, closing a stake of 28,615 shares — an estimated $341K sold.

Ergoteles first reported a position in CASI in Q2 2021 and held it in 2 quarters. The position peaked at $466K in Q2 2021. 51 funds tracked by Wall St. Rank hold CASI as of Q4 2021.

  • Ergoteles reported no remaining CASI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 28,615 CASI Pharmaceuticals shares in Q4 2021, an estimated $341K.
  • Ergoteles first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Ergoteles's CASI Pharmaceuticals position peaked at $466K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.